. "Foundation of serum bank based on long-term monitored patients with prostate cancer, offering the possibility of verification of any association between newly identified oncomarkers and the disease progression."@en . "http://www.isvav.cz/projectDetail.do?rowId=NT13472"^^ . "2014-03-21+01:00"^^ . . "2015-01-22+01:00"^^ . . . . . "\u010Casn\u00E1 identifikace mu\u017E\u016F, kte\u0159\u00ED maj\u00ED vysok\u00E9 riziko recidivy karcinomu prostaty po prim\u00E1rn\u00ED l\u00E9\u010Db\u011B je podstatn\u00E1 pro dal\u0161\u00ED eventu\u00E1ln\u00ED terapeutick\u00FD z\u00E1sah do ji\u017E tak nep\u0159\u00EDzniv\u00E9ho v\u00FDvoje relapsu n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED. \u00DAskal\u00ED v\u00FDzkumu v t\u00E9to oblasti spo\u010D\u00EDv\u00E1 v rozvlekl\u00E9m procesu, kter\u00FD vede od identifikace nov\u00E9ho potencion\u00E1ln\u00EDho onkomarkeru k dlouhodob\u00E9mu sledov\u00E1n\u00ED zm\u011Bn jeho s\u00E9rov\u00E9 koncentrace ve vztahu k biochemick\u00FDm a klinick\u00FDm zn\u00E1mk\u00E1m progrese karcinomu. Na\u0161\u00EDm z\u00E1m\u011Brem je zalo\u017Een\u00ED s\u00E9rov\u00E9 banky dlouhodob\u011B sledovan\u00FDch pacient\u016F s karcinomem prostaty, \u010D\u00EDm\u017E vznikne mo\u017Enost opakovan\u00E9ho testov\u00E1n\u00ED vztahu rozli\u010Dn\u00FDch onkomarker\u016F k progresi onemocn\u011Bn\u00ED s t\u00E9m\u011B\u0159 okam\u017Eit\u00FDm v\u00FDsledkem dlouhodob\u011B sledovan\u00E9 kohorty pacient\u016F. Na velmi slibn\u00FD predik\u00E1tor progrese karcinomu prostaty poukazuj\u00ED i v\u00FDsledky na\u0161ich pilotn\u00EDch studi\u00ED. Zab\u00FDv\u00E1me se detailn\u00EDm studiem poopera\u010Dn\u00ED dynamiky PSA ve velmi n\u00EDzk\u00FDch hladin\u00E1ch pomoc\u00ED ultrasenzitivn\u00EDho testu. Tyto v\u00FDsledky je t\u0159eba ov\u011B\u0159it na v\u011Bt\u0161\u00EDm souboru dlouhodob\u011B sledovan\u00FDch pacient\u016F." . . . "1"^^ . "2015-12-31+01:00"^^ . . "1"^^ . "1"^^ . "Early identification of patients who are at high risk of prostate cancer recurrence after the primary treatment is essentials for the success of eventual secondary therapy. The disadvantage of research on this subject is the long-lasting process going from the identification of novel tumor-marker to the monitoring of changes of this tumor-marker\u2019s serum concentrations in association with the biochemical or clinical progression of the disease. Our aim is to create a unique serum bank of clinically long-term followed-up patients with prostate cancer, which would allow us to assess biochemical, immunological and other changes in serum. Such an approach may provide us a quick insight into the mechanism of prostate cancer progression in a long term. Results of our pilot study point at novel parameters derived from the detailed analyze of postoperative PSA assessed with ultrasensitive assay. These findings have to be confirmed on larger sample of patients."@en . . "1"^^ . "prostate cancer - recurrence -"@en . . "Vytvo\u0159en\u00ED s\u00E9rov\u00E9 banky dlouhodob\u011B sledovan\u00FDch pacient\u016F s karcinomem prostaty s mo\u017Enost\u00ED ov\u011B\u0159en\u00ED spojitosti nov\u011B identifikovan\u00FDch onkomarker\u016F s progn\u00F3zou onemocn\u011Bn\u00ED." . "2012-04-01+02:00"^^ . . "NT13472" . . . "0"^^ . . . .